Abstract: EP1691
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Objective: Interferon-β has been approved for the treatment of relapsing-remitting (RR) multiple sclerosis (MS), whereas its efficacy in preventing long-term disability and conversion to secondary progressive (SP) MS is still debated. We aim to compare the long-term clinical evolution of newly-diagnosed RRMS patients treated with different Interferon-β formulations.
Methods: 507 patients were included in the analysis and followed-up for 8.5±3.9 years. 37.6% were treated with subcutaneous Interferon-β1a (Interferon-β1a 44mcg), 33.4% with intramuscular Interferon-β1a (Interferon-β1a 30mcg), and 29.0% with subcutaneous Interferon-β1b (Interferon-β1b 250mcg). Relapse occurrence, 1-point EDSS progression, reaching of EDSS 4.0 and conversion to SP were recorded as outcome measures. To reduce the selection bias, we calculated the propensity score of receiving the specific treatment considering age (32.7±8.3 years), gender (female 63.1%), disease duration (2.7±2.8 years), and baseline EDSS (1.5, range 1.0-3.5). Propensity score and covariates (age, gender, disease duration and EDSS) were included in the statistical models.
Results: At Cox regression models, the reaching of EDSS 4.0 was 20% higher for Interferon-β1b 250mcg (HR=1.207; p=0.063), and 30% higher for Interferon-β1a 30mcg (HR=1.363; p=0.095), when compared with Interferon-β1a 44mcg. The rate of SP conversion was 100% higher for Interferon-β1b 250mcg (HR=2.054; p=0.042), and 80% higher for Interferon-β1a 30mcg (HR=1.884; p=0.081), when compared with Interferon-β1a 44mcg.
Conclusion: Patients treated with Interferon-β1a 44mcg presented with a marginally reduced risk of disability accrual in the long-term, when compared with Interferon-β1b 250mcg and, at least in part, with Interferon-β1a 30mcg. Formulation, frequency of administration and dose of Interferon-β might affect the long-term clinical evolution of RRMS.
Disclosure:
Marcello Moccia has received grant from the ECTRIMS-MAGMNISM fellowship program, honoraria and travel support form Almirall, Coloplast, Genzyme, and Merck-Serono.
Raffaele Palladino has nothing to disclose.
Antonio Carotenuto has nothing to disclose.
Francesco Sacca´ has received honoraria and travel support from Almirall, Biogen, Genzyme, Merck-Serono and Novartis.
Cinzia Valeria Russo has nothing to disclose.
Roberta Lanzillo has received honoraria and travel support from Almirall, Biogen, Genzyme, Merck-Serono and Novartis.
Vincenzo Brescia Morra has received honoraria and travel support from Almirall, Bayer, Biogen, Genzyme, Merck-Serono, Novartis and TEVA.
Abstract: EP1691
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Objective: Interferon-β has been approved for the treatment of relapsing-remitting (RR) multiple sclerosis (MS), whereas its efficacy in preventing long-term disability and conversion to secondary progressive (SP) MS is still debated. We aim to compare the long-term clinical evolution of newly-diagnosed RRMS patients treated with different Interferon-β formulations.
Methods: 507 patients were included in the analysis and followed-up for 8.5±3.9 years. 37.6% were treated with subcutaneous Interferon-β1a (Interferon-β1a 44mcg), 33.4% with intramuscular Interferon-β1a (Interferon-β1a 30mcg), and 29.0% with subcutaneous Interferon-β1b (Interferon-β1b 250mcg). Relapse occurrence, 1-point EDSS progression, reaching of EDSS 4.0 and conversion to SP were recorded as outcome measures. To reduce the selection bias, we calculated the propensity score of receiving the specific treatment considering age (32.7±8.3 years), gender (female 63.1%), disease duration (2.7±2.8 years), and baseline EDSS (1.5, range 1.0-3.5). Propensity score and covariates (age, gender, disease duration and EDSS) were included in the statistical models.
Results: At Cox regression models, the reaching of EDSS 4.0 was 20% higher for Interferon-β1b 250mcg (HR=1.207; p=0.063), and 30% higher for Interferon-β1a 30mcg (HR=1.363; p=0.095), when compared with Interferon-β1a 44mcg. The rate of SP conversion was 100% higher for Interferon-β1b 250mcg (HR=2.054; p=0.042), and 80% higher for Interferon-β1a 30mcg (HR=1.884; p=0.081), when compared with Interferon-β1a 44mcg.
Conclusion: Patients treated with Interferon-β1a 44mcg presented with a marginally reduced risk of disability accrual in the long-term, when compared with Interferon-β1b 250mcg and, at least in part, with Interferon-β1a 30mcg. Formulation, frequency of administration and dose of Interferon-β might affect the long-term clinical evolution of RRMS.
Disclosure:
Marcello Moccia has received grant from the ECTRIMS-MAGMNISM fellowship program, honoraria and travel support form Almirall, Coloplast, Genzyme, and Merck-Serono.
Raffaele Palladino has nothing to disclose.
Antonio Carotenuto has nothing to disclose.
Francesco Sacca´ has received honoraria and travel support from Almirall, Biogen, Genzyme, Merck-Serono and Novartis.
Cinzia Valeria Russo has nothing to disclose.
Roberta Lanzillo has received honoraria and travel support from Almirall, Biogen, Genzyme, Merck-Serono and Novartis.
Vincenzo Brescia Morra has received honoraria and travel support from Almirall, Bayer, Biogen, Genzyme, Merck-Serono, Novartis and TEVA.